Syngene International finalizes Rs 617cr acquisition of biologics facility from Stelis Biopharma
Syngene International has announced the conclusion of its acquisition of a multi-modal biologics manufacturing facility, known as ‘Unit 3’, from Stelis Biopharma Ltd. The deal ... Read More
Syngene to acquire Stelis Biopharma’s biologics manufacturing facility in Bangalore
Pharma manufacturing services company Syngene International has unveiled plans to acquire Unit 3 biologics manufacturing facility located in Bangalore, India from Stelis Biopharma Limited (SBL). ... Read More
Strides Pharma Science’s CDMO unit gets FDA EIR for Bengaluru facility
Strides Pharma Science said that its biologics arm Stelis Biopharma has secured an establishment inspection report (EIR) from the US Food and Drug Administration (FDA) ... Read More
Stelis Biopharma appoints Mark W. Womack as CEO
Stelis Biopharma Limited, a biopharma and vaccines company and the biotech arm of Strides Pharma Science has appointed Mark W. Womack as its new chief ... Read More